In house colorimetric reverse hybridisation assay for detection of the mutation most frequently associated with resistance to isoniazid in Mycobacterium tuberculosis

Memorias do Instituto Oswaldo Cruz

Volumn 104, Issue 5, 2009, Pages 710-714

  Verza, Mirela ^a,b   Maschmann, Raquel de Abreu ^a,b   Silva, Márcia Susana Nunes ^a,c   Costa, Elis Regina Dalla ^a,d   Ribeiro, Marta Osório ^a   Rosso, Franciele ^a,b   Suffys, Philip Noel ^e   Tortoli, Enrico ^f   Marcelli, Fiorella ^f   Zaha, Arnaldo ^b   Rossetti, Maria Lucia Rosa ^a,c  

^a Fundacao Estadual de Producao e Pesquisa em Saude   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e INSTITUTO OSWALDO CRUZ   (Brazil)

^f CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Drug resistance; Isoniazid; KatG315; Reverse hybridization assay; Tuberculosis

Indexed keywords

MYCOBACTERIUM TUBERCULOSIS;

EID: 70349696255     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762009000500008     Document Type: Article

References (32)

1. Abate G, Hoffner SE, Thomsen VO, Miorner H 2001. Characterization of isoniazid-resistant strains of Mycobacterium tuberculosis on the basis of phenotypic properties and mutations in katG. Eur J Clin Microbiol Infect Dis 20: 329-333.
2. Dalla Costa ER, Ribeiro MO, Silva MSN, Arnold LS, Rostirolla DC, Cafrune PI, Espinoza RC, Palaci M, Telles MA, Ritacco V, Suffys PN, Lopes ML, Campelo CL, Miranda SS, Kremer K, Silva PEA, Fonseca LS, Ho JL, Kritski AL, Rossetti MLR 2009. Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America. BMC Microbiol 9: 39.
3. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim, SJ, Reniero A, Hoffner S, Rieder HL, Binkin N, Dye C, Williams R, Raviglione MC 2001. Global trends in resistance to antituberculosis drugs. N Engl J Med 344: 1294-1303.
4. Hazbon MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, Varma-Basil M, Billman-Jacobe H, Lavender C, Fyfe J, Garcia-Garcia L, Leon CI, Bose M, Chaves F, Murray M, Eisenach KD, Sifuentes-Osornio J, Cave MD, Ponce de Leon A, Alland D 2006. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 50: 2640-2649.
5. Hermans PWM, Soolingen DV, Dale JW Schuitema ARJ, Mcadam RA, Catty D, Van Embden JDA 1990. Insertion element IS986 from Mycobacterium tuberculosis: a useful tool for diagnosis and epidemiology of tuberculosis. J Clin Microbiol 28: 2051-2058.
6. Heym B, Cole ST 1992. Isolation and characterization of isoniazid-resistant mutants of Mycobacterium smegmatis and M. aurum. Res Microbiol 143: 721-730.
7. Hillemann D, Kubica T, Agzamova R, Venera B, Rusch-Gerdes S, Niemann S 2005. Rifampicin and isoniazid resistance mutations in Mycobacterium tuberculosis strains isolated from patients in Kazakhstan. Int J Tuberc Lung Dis 9: 1161-1167.
8. Jiao WW, Mokrousov I, Sun GZ, Li M, Liu JW, Narvskaya O, Shen, AD 2007. Molecular characteristics of rifampin and isoniazid resistant Mycobacterium tuberculosis strains from Beijing, China. Chin Med J (Engl) 120: 814-819.
9. Kapetanaki SM, Chouchane S, Yu S, Zhao X, Magliozzo RS, Schelvis JP 2005. Mycobacterium tuberculosis KatG (S315T) catalaseperoxidase retains all active site properties for proper catalytic function. Biochemistry 44: 243-252.
10. Makinen J, Marttila HJ, Marjamaki M, Viljanen MK, Soini H 2006. Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 44: 350-352.
11. Mdluli K, Sherman DR, Hickey MJ 1996. Biochemical and genetic data suggest that inhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis. J Infect Dis 174: 1085-1090.
12. Mdluli K, Slayden RA, Zhu Y, Ramaswamy S, Pan X, Mead D, Crane DD, Musser JM, Barry III CE 1998. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science 280: 1607-1610.
13. Mokrousov I, Narvskaya O, Otten T, Limeschenko E, Steklova L, Vyshnevskiy B 2002. High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from Northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother 46: 1417-1424.
14. Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden JD 1996. Characterization of the catalaseper-oxidase gene (katG) and inhA locus in isoniazid-resistant and - susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis 173: 196-202.
15. Parsons LM, Somoskovi A, Urbanczik R, Salfingerm M 2004. Laboratory diagnostic aspects of drug resistant tuberculosis. Front Biosci 9: 2086-2105.
16. Pym AS, Saint-Joanis B, Cole ST 2002. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 70: 4955-4960.
17. Ramaswamy SV, Reich R, Dou SJ, Jasperse L, Pan X, Wanger A, Quitugua T, Graviss EA 2003. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 47: 1241-1250.
18. Rawat R, Whitty A, Tonge PJ 2003. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc Natl Acad Sci USA 100: 13881-13886.
19. Saint-Joanis B, Souchon H, Wilming M, Johnsson K, Alzari PM, Cole ST 1999. Use of site-directed mutagenesis to probe the structure, function and isoniazid activation of the catalase/peroxidase, KatG, from Mycobacterium tuberculosis. Biochem J 338: 753-760.
20. Silva MS, Senna SG, Ribeiro MO, Valim AR, Telles MA, Kritski A, Morlock GP, Cooksey RC, Zaha A, Rossetti ML 2003. Mutations in katG, inhA and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis. J Clin Microbiol 41: 4471-4474.
21. Suresh N, Singh UB, Gupta C, Arora J, Rana T, Samantaray JC 2007. Rapid detection of rifampin-resistant Mycobacterium tuberculosis directly from stained sputum smears using single-tube nested polymerase chain reaction deoxyribonucleic acid sequencing. Diagn Microbiol Infect Dis 58: 217-222.
22. van Doorn HR, De Haas PE, Kremer K, Vandenbroucke-Grauls CM, Borgdorff MW, van Soolingen D 2006. Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of experience in The Netherlands. Clin Microbiol Infect 12: 769-775.
23. van Doorn HR, Kuijper EJ, van der Ende A, Welten AG, van Soolingen D, de Haas PE, Dankert J 2001. The susceptibility of Mycobacterium tuberculosis to isoniazid and the Arg-Leu mutation at codon 463 of katG are not associated. J Clin Microbiol 39: 1591-1594.
24. van Rie A, Warren R, Mshanga I, Jordaan AM, van der Spuy GD, Richardson M, Simpson J, Gie RP, Enarson DA, Beyers N, van Helden PD, Victor TC 2001. Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community. J Clin Microbiol 39: 636-641.
25. van Soolingen D, De Hass PE, Hermans PWM, Van Embden JDA 1994. DNA Fingerprinting of Mycobacterium tuberculosis. Methods Enzymol 235: 196-204.
26. van Soolingen D, De Haas PE, van Doorn HR, Kuijper E, Rinder H, Borgdorff MW 2000. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis 182: 1788-1790.
27. Victor TC, Jordaan AM, van Rie A, van der Spuy GD, Richardson M, van Helden PD, Warren R 1999. Detection of mutations in drug resistance genes of Mycobacterium tuberculosis by a dot-blot hybridization strategy. Tuber Lung Dis 79: 343-348.
28. Wei CJ, Lei B, Musser JM, Tu SC 2003. Isoniazid activation defects in recombinant Mycobacterium tuberculosis catalase-peroxidase (KatG) mutants evident in InhA inhibitor production. Antimicrob Agents Chemother 47: 670-675.
29. WHO - World Health Organization 2008. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TB/2008.393. Available from: http://www.who.int/tb/publications/global_report/2008/pdf/fullreport.pdf.
30. Zakerbostanabad S, Titov LP, Bahrmand AR 2008. Frequency and molecular characterization of isoniazid resistance in katG region of MDR isolates from tuberculosis patients in southern endemic border of Iran. Infect Genet Evol 8: 15-19.
31. Zhang M, Yue J, Yang YP, Zhang HM, Lei, JQ, Jin RL, Zhang XL, Wang HH 2005. Detection of mutations associated with isoniazid resistance in Mycobacterium tuberculosis isolates from China. J Clin Microbiol 43: 5477-5482.
32. Zumla A, Grange JM 2001. Multidrug-resistant tuberculosis - can the tide be turned? Lancet Infect Dis 1: 199-202.